Drug intelligence / Profile preview

Theavit

Development stage: Preclinical
Lead developer: Théa Pharmaceuticals
Administration: Oral

Overview

Theavit is a nutritional supplement developed by Laboratorios Thea, Spain, formulated with antioxidants and minerals. These components are provided in doses compliant with European Union regulations, mirroring the recommendations from the Age-Related Eye Disease Study (AREDS). The supplement is intended for patients with age-related macular degeneration (AMD), specifically those with severe AMD or unilateral wet AMD, with the primary goal of slowing the progression of the disease.

Brand names: Theavit

Beyond the preview

Go deeper on Theavit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theavit.

Explore the full profile